diazepam (valium) Report issue

Small molecule Approved FDA
AACT ChEMBL DrugBank Drug Central Drugs@FDA KEGG MeSH PubChem repoDB

Active Ingredient History

NOW
  • Now
Diazepam is a benzodiazepine first discovered at Hoffman-La Roche in the late 1950s. Diazepam was approved by FDA for the treatment of anxiety disorders as well as for such conditions as skeletal muscle spasm, alcohol withdrawal syndrom and convulsions (under the most known brand Valium). The drug acts by binding to GABA-A receptors and potentiating GABA evoked current. Chronic diazepam use is associated with tolerance, dependence, and withdrawal.   NCATS

Chemistry

  • SMILES: CN1C2=CC=C(Cl)C=C2C(=NCC1=O)C3=CC=CC=C3
  • InChIKey: AAOVKJBEBIDNHE-UHFFFAOYSA-N
  • Mol. Mass: 284.74
  • ALogP: 3.15
  • ChEMBL Molecule:
    diazepam  
More Chemistry

Pharmacology

Drug Pricing (per unit)

United States

$0.0208 - $336.3064

Australia

$0.0254 - $24.7011
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

Alternative names

7-chloro-1,3-dihydro-1-methyl-5-phenyl-2h-1,4-benzodiazepin-2-one | alupram 10 | alupram 2 | alupram 5 | apozepam | atensine | dialar | dialar fte | diastat | diastat acudial | diazemuls | diazepam | diazepam intensol | dizac | e-pam | la-iii | methyl diazepinone | paxel | q-pam | relanium | ro-52807 | ro-5-2807 | scriptopam | serenack | solis | stesolid | tensium | tranimul | valclair | valium | valrelease | vivol | wy-3467

Organizations (100)

Research & Development (71)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (33)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (49)

Approved Indications (6)


 

Alcohol Withdrawal Delirium (approved 1963)

Anxiety Disorders (approved 1963)

Epilepsy

Muscle Spasticity (approved 1963)

Psychomotor Agitation

Seizures (approved 1963)

Experimental Indications - Clinical Trial Phases 1-4 (47)


 

Abdominal Pain (Phase 2)

Alcoholism (Phase 4)

Alcohol Withdrawal Delirium (Phase 4)

Anterior Cruciate Ligament Injuries (Phase 2/Phase 3)

Anti-Anxiety Agents (Phase 4)

Anxiety ()

Anxiety Disorders (Phase 3)

Arthritis, Rheumatoid (Phase 1)

Behavior (Phase 4)

Cannabinoids (Phase 2)

Cerebral Palsy (Phase 4)

Crying (Phase 4)

Dementia (Phase 3)

Dental Care for Disabled (Phase 4)

Depression (Phase 3)

Dronabinol (Phase 2)

Drug Resistant Epilepsy (Phase 2)

Epilepsies, Partial (Phase 3)

Epilepsy ()

Epilepsy, Complex Partial (Phase 3)

Epilepsy, Generalized (Phase 3)

Healthy Volunteers (Phase 1)

Infertility (Phase 4)

Labor, Obstetric (Phase 2)

Landau-Kleffner Syndrome (Phase 2/Phase 3)

Low Back Pain (Phase 4)

Marijuana Abuse (Phase 1/Phase 2)

Meniscus (Phase 1)

Metabolism (Phase 1)

Methamphetamine (Phase 4)

Narcotics (Phase 3)

Opiate Overdose (Phase 4)

Pain (Phase 4)

Pain, Postoperative (Phase 4)

Pancreatitis, Chronic (Phase 2)

Pelvic Floor Disorders (Phase 4)

Pelvic Pain (Phase 2)

Psychophysiologic Disorders (Phase 3)

Rotator Cuff Injuries (Phase 2)

Schizophrenia (Phase 3)

Seizures (Phase 4)

Seizures, Febrile (Phase 4)

Sleep Wake Disorders (Phase 4)

Status Epilepticus (Phase 3)

Stress Disorders, Post-Traumatic (Phase 4)

Substance Abuse, Oral (Phase 4)

Whiplash Injuries (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 73
  • # of Trial Organizations: 71

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue